EKF Diagnostics Holdings plc

Equities

EKF

GB0031509804

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 11:35:27 2024-05-28 am EDT			5-day change	1st Jan Change
32 ^GBX	-3.03%		-0.62%	+1.11%

May. 15	Future Metals celebrates state government grant	AN
May. 14	EKF Diagnostics Holdings Says Q1 Adj EBITDA Shows About 20% Improvement	RE

Dividend confirmation

October 26, 2021 at 04:26 am EDT

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that the Board has confirmed a cash dividend of 1.1p per ordinary share which will be paid on 1 December 2021.

The dividend timetable dates are below:

Ex-dividend date:	4 November 2021
Record date:	5 November 2021
Payment date:	1 December 2021

For further information please contact:

EKF Diagnostics Holdings plc		www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman		Tel: +44 (0)29 2071 0570
Mike Salter, CEO
Richard Evans, FD & COO

Singer Capital Markets (Nominated Adviser & Joint Broker)			Tel: +44 (0)20 7496 3000
Aubrey Powell / George Tzimas / Tom Salvesen

Investec Bank plc (Joint Broker)		Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams

Walbrook PR Limited	Tel: +44 (0)20 7933 8780 or
Paul McManus / Lianne Cawthorne	Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

Attachments

Original document
Permalink

Disclaimer

EKF Diagnostics Holdings plc published this content on 25 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2021 08:25:04 UTC.

Latest news about EKF Diagnostics Holdings plc

Future Metals celebrates state government grant	May. 15	AN
EKF Diagnostics Holdings Says Q1 Adj EBITDA Shows About 20% Improvement	May. 14	RE
Onward Opportunities' small-cap strategy yields solid results in 2023	Apr. 11	AN
EKF Diagnostics says prospects "promising" but pauses dividends	Mar. 20	AN
EKF Diagnostics Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
EKF Diagnostics reports trading in line with expectations	Jan. 29	AN
EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023	Jan. 29	CI
EKF Diagnostics Holdings plc Announces the Official Opening of its New State-Of-The-Art Life Sciences Manufacturing Site in South Bend, Indiana, United States	23-10-26	CI
EARNINGS: FireAngel Safety interim loss widens amid ongoing headwinds	23-09-26	AN
Earnings Flash (EKF.L) EKF DIAGNOSTICS HOLDINGS Reports H1 Revenue GBP26.9M	23-09-26	MT
EKF Diagnostics Holdings plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
FTSE 100 Closes Tuesday Up 0.41% as Oil-Price Rises Benefit the Index	23-09-12	DJ
EKF Diagnostics hires CFO from Trellus Health, latter names successor	23-09-12	AN
FTSE 100 Rises, Led by AB Foods; Smurfit Kappa Slides	23-09-12	DJ
Trellus Health's Interim Finance Head Takes Full-time CFO Role at EKF Diagnostics	23-09-12	MT
EKF Diagnostics Holdings plc Provides Financial Guidance for the Year Ending 31 December 2023	23-09-12	CI
EKF Diagnostics Holdings plc Appoints Stephen Young as Chief Financial Officer	23-09-12	CI
Revolution Bars reports good progress from Peach Pubs	23-07-26	AN
FTSE 100 Closes Down 0.2% as Miners Offset Ocado, -2-	23-07-26	DJ
FTSE 100 Closes Up 0.5% as Sage Group Shines	23-06-28	DJ
SONIA Illiquidity Could Explain Disconnect in BOE Peak Rate Pricing	23-06-28	DJ
EKF Diagnostics says CFO Davies resigns to pursue other opportunities	23-06-28	AN
EKF Diagnostics CFO Plans Exit; Successor to Assume Role in Q4	23-06-28	MT
Marc Davies to Step Down as Chief Financial Officer of EKF Diagnostics Holdings plc	23-06-28	CI
EKF Diagnostics announces enzyme fermenter progress	23-06-20	AN

Chart EKF Diagnostics Holdings plc

Duration

Period

More charts

Company Profile

EKF Diagnostics Holdings plc is a United Kingdom-based diagnostics company. The Company is engaged in point-of-care testing, central laboratory tests, enzyme manufacturing and the provision of contract manufacturing services to the healthcare industry. Its principal activity is the development, manufacture and supply of products into the in-vitro diagnostics marketplace. Its point of care analyzers is designed for use within doctors' surgeries, clinics, blood banks and hospital and private laboratories to provide results. Its life sciences specialize in producing enzymes and contracted custom products for use in medical diagnostics, pharmaceuticals and industry. Its life science facilities are based in two locations in Indiana, United States. Its central laboratory division manufactures a spectrum of reagents for use in hospital laboratories. Its contract manufacturing business provides specialized services to the diagnostics and healthcare industries for the production of custom kits.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-09-09 - Q2 2024 Earnings Release (Projected)

More about the company